Albert Einstein once said, "Reality is merely an illusion, albeit a very persistent one. " But what if I told you that your brain is shaping that illusion every second? Imagine a scenario where two different people are stuck in traffic. One is frustrated, holding on to the wheel, thinking, "Why does this always happen to me. Now, at the same time, the other person looks at the delay in a unique way.A chance to enjoy their favorite podcast. Same situation, completely different experiences. Why.There is just ...

It's about the intersection of tradition and innovation when it comes to neuroscience, the brain science. How about that. What do you think about it.Somewhere around 2,500 years ago, the Buddhist monks used to be sitting and doing mindful meditation, claiming that is actually transforming the minds. But today, us neuroscientists in academia, in top-notch academic centers, we sit, we think, and we formulate ways to understand the brain dynamics. We attach sensors to the brain surface. We use other methods to ...

[Applause] You're not actually looking at me right now. What you're seeing is your brain's best guess. Your eyes aren't windows that you're looking through.What's happening is far stranger. Your brain takes millions of sensory signals, filters them through your memories, beliefs, and expectations, and then renders its version of the external world. What you're seeing is an internal image.This is what neuroscientists call the active inference model of the brain. But here's where it gets even more strange. It ...

Core Insights - JAZZ Pharmaceuticals is a unique player in the cannabis sector, focusing on an FDA-approved drug, Epidiolex, rather than traditional cannabis cultivation or sales [1][2] - Epidiolex has become a significant growth driver for JAZZ, contributing over 25% of total product sales and showing a 5% year-over-year increase in sales [3][4] - The global medical cannabis market is projected to exceed $130 billion by 2032, providing JAZZ with a competitive advantage as one of the few established pharmaceutical firms with an FDA-approved cannabis product [5] Company Overview - JAZZ Pharmaceuticals has diversified its portfolio beyond cannabis, maintaining strong positions in neuroscience and oncology [6] - The company's neuroscience segment benefits from the oxybate franchise, particularly Xywav, which is a low-sodium treatment for narcolepsy and idiopathic hypersomnia [7] - JAZZ's oncology portfolio, including drugs like Defitelio and Vyxeos, contributed nearly 28% of product sales in the first half of 2025 [8] Recent Developments - The acquisition of Chimerix for $935 million added Modeyso, an FDA-approved drug for glioma patients, enhancing JAZZ's oncology offerings [9] - Despite setbacks in pipeline development, including the discontinuation of suvecaltamide and underwhelming results for JPZ150, JAZZ continues to explore options for its drug pipeline [10][11] Financial Performance - JAZZ's stock has increased by 5% year-to-date, outperforming the industry average of 4% [12] - EPS estimates for 2025 and 2026 have shown an upward trend, contrasting with declines in estimates for pure-play cannabis companies [13] Market Position - JAZZ Pharmaceuticals is positioned as a balanced biopharma investment, offering exposure to both neuroscience and oncology, with Epidiolex providing a unique entry into the cannabis therapeutics market [16][17]

[Applause] Thank you. Um, so I'm Yugo. I'm onethird of Obvious.We are a trio of artists that create with artificial intelligence. Uh, so um, the backstory behind our collective is that we are free friends from childhood. So I've known Goi and Pierre uh, since uh, basically high school.And uh our vision is to create with artificial intelligence uh not only to uh create new aesthetics and to explore this new medium but also to talk about uh the social implication of the emergence of such uh technology. And so ...

Core Insights - Contineum Therapeutics, Inc. announced positive topline data from its PIPE-791 Phase 1b PET trial, achieving its primary objectives [1] Company Overview - Contineum Therapeutics is a clinical-stage biopharmaceutical company focused on developing differentiated therapies for neuroscience, inflammation, and immunology indications [1]

[Music] I am going to show you a drawing of a man's face. He has dark hair, a wide set jaw, and a slightly crooked nose. How would you describe his facial expression.Now, I'm going to show you a drawing of a woman sitting on the ground. Her gaze is cast downwards. What do you think she's thinking.Can you see both the man's face and the woman. But the image isn't changing. The sensory input entering your eyes is not changing.Only your thoughts are changing. You may think that your thoughts are just yours, bu ...

Johnson & Johnson FY Conference Summary Company Overview - **Company**: Johnson & Johnson (NYSE: JNJ) - **Date**: September 10, 2025 - **Speakers**: Joaquin Duato (Chairman and CEO), John Reed (Executive Vice President, Head of Pharma R&D) Key Industry Insights - **Policy Environment**: The company is actively engaging with U.S. policymakers regarding tariffs and manufacturing investments, emphasizing a $55 billion investment program over the next five years to enhance U.S. manufacturing capabilities [2][6][7]. - **Innovation Focus**: Johnson & Johnson is experiencing significant innovation, particularly in the pharmaceutical sector, with a strong pipeline in oncology, immunology, and neuroscience [3][12][13]. Core Product Developments - **Elexo Approval**: A new product, Elexo, was approved for localized bladder cancer, projected to be a $5 billion platform, with some estimates suggesting up to $8 billion potential [3][5]. - **Oncology Goals**: The company aims to become the number one oncology company by 2030, targeting $50 billion in sales, with strong growth in multiple myeloma and prostate cancer franchises [13][14]. - **Immunology Pipeline**: The focus is on Tremfya and the upcoming Icotrochimab, which is expected to be a major growth driver due to its oral administration and efficacy comparable to biologics [15][46]. Financial Performance - **Growth Trajectory**: Johnson & Johnson reported strong growth in the second quarter, exceeding expectations in both revenue and earnings per share (EPS), despite facing biosimilar competition [5][25]. - **Future Projections**: The company anticipates continued growth, with expectations that 2026 will outperform 2025, and 2027 will be better than 2026 [25]. MedTech Segment - **MedTech Strategy**: The company aims to be a leader in MedTech, focusing on high-growth markets such as cardiology and robotic surgery, with a commitment to innovation across its portfolio [30][31]. - **Cardiovascular Growth**: The cardiovascular segment saw a 22% growth in the second quarter, driven by acquisitions and innovative products [34]. Research and Development Highlights - **Alzheimer's Research**: Johnson & Johnson is investing heavily in Alzheimer's research, particularly targeting tau proteins, with ongoing phase two studies that could significantly impact treatment options [56][60]. - **Combination Therapies**: The company is exploring combination therapies in immunology, aiming to improve outcomes for patients with inflammatory bowel disease (IBD) [54][52]. Market Position and Competitive Landscape - **Community Engagement**: The company is focused on ensuring that new therapies are manageable for community oncologists, emphasizing safety and tolerability [28]. - **Business Development Focus**: Johnson & Johnson is prioritizing early-stage opportunities for significant value creation, with a history of successful smaller deals leading to major product launches [40][41]. Conclusion Johnson & Johnson is positioned for robust growth through strategic investments in innovation, a strong product pipeline, and a commitment to addressing unmet medical needs across various therapeutic areas. The company's proactive engagement with policymakers and focus on high-growth MedTech markets further solidifies its competitive edge in the industry.

Core Insights - AbbVie has developed a strong neuroscience franchise, initially driven by blockbuster drugs like Botox Therapeutic and Vraylar, and has expanded its portfolio with new migraine treatments Qulipta and Ubrelvy, as well as Vyalev for Parkinson's disease [1][2]. Financial Performance - The neuroscience segment contributed over 17% to AbbVie's total sales in the first half of 2025, with revenues growing nearly 21% year over year, primarily due to increased sales of Botox Therapeutic and Vraylar, along with rising uptake of Ubrelvy and Qulipta [2][9]. - The strong performance in the neuroscience segment has helped mitigate the decline in Duodopa sales [2][9]. Product Launches and Acquisitions - AbbVie launched Vyalev in the U.S. earlier this year, and while initial sales have been modest, expectations are for its contribution to total revenues to grow over time [3]. - The company is actively investing in new therapies, including a recent agreement to acquire Gilgamesh Pharmaceuticals' lead pipeline drug for approximately $1.2 billion, which targets major depressive disorder (MDD). This follows a $1.4 billion acquisition of Aliada Therapeutics, which added an investigational antibody for Alzheimer's disease (AD) [4][5]. Competitive Landscape - Major competitors in the neuroscience space include Biogen and Johnson & Johnson. Biogen is diversifying its offerings due to declining revenues in its multiple sclerosis franchise and has partnered with Eisai to market an FDA-approved treatment for Alzheimer's disease [6]. - Johnson & Johnson has a strong neuroscience portfolio, including the antidepressant nasal spray Spravato and the antipsychotic Invega Sustenna, and recently acquired Intra-Cellular Therapies to enhance its offerings [7]. Valuation and Market Performance - AbbVie shares have outperformed the industry year to date, trading at a premium with a price/earnings (P/E) ratio of 15.59, compared to the industry average of 14.84 and above its five-year mean of 12.82 [8][11]. - Earnings per share (EPS) estimates for 2025 and 2026 have seen slight increases in the past 30 days [12].

Summary of Continuum Therapeutics (CTNM) 2025 Conference Call Company Overview - Continuum Therapeutics is a San Diego-based biotech company focused on neuroscience, inflammation, and immunology [3][4] - The company has two clinical-stage assets and is pursuing multiple therapeutic areas with important clinical proof of concept readouts expected [4] Key Programs PIPE-791 - PIPE-791 is a first-in-class selective inhibitor of the LPA1 receptor, currently in development for idiopathic pulmonary fibrosis (IPF) [5][16] - The unmet need in IPF is significant, with approximately 130,000 patients in the US and 3 million worldwide, and existing treatments are considered suboptimal [7][8] - Current treatments, such as Nintendonib and Prophenidone, have tolerability issues leading to high dropout rates [15] - The LPA1 receptor is linked to fibrosis and inflammation, making it a critical target for IPF treatment [16][17] - Continuum believes that PIPE-791 has a unique pharmacokinetic (PK) profile that allows for high target coverage and improved tolerability compared to existing therapies [21][25] PIPE-307 - PIPE-307 is a muscarinic receptor antagonist being evaluated in relapse and remitting multiple sclerosis (MS) [49] - The program is based on prior studies that demonstrated the potential for muscarinic receptor antagonism to improve remyelination [51] - The Phase II study is designed to measure low contrast letter acuity and other functional biomarkers [57] Clinical Development and Strategy - Continuum plans to initiate a global Phase II proof of concept study for PIPE-791 in the fourth quarter, with a focus on safety, tolerability, and efficacy [30][31] - The company is also conducting a PET receptor occupancy study to validate dosing for PIPE-791 [34][36] - The chronic pain program is exploratory, focusing on osteoarthritis and chronic lower back pain, with a small Phase Ib study planned [39][45] Market Landscape - The IPF treatment market is viewed as an untapped opportunity, with existing therapies generating significant sales despite their limitations [29] - Continuum anticipates that a safer and more effective drug could carve out a significant space in the IPF treatment landscape, which is currently lacking in effective options [27][28] Upcoming Catalysts - Key upcoming catalysts include the pain study readout in the first half of next year and the initiation of the IPF study [47] - The company is also monitoring BMS' top-line data, expected in the second half of next year, as a benchmark for its own programs [48] Conclusion - Continuum Therapeutics is positioned to address significant unmet needs in IPF and MS with its innovative drug candidates, backed by a robust clinical development strategy and a focus on improving patient outcomes through enhanced tolerability and efficacy [64]